• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Instil Bio Inc.

    4/15/21 4:09:35 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email
    SC 13G 1 tm2112992d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. )*

     

    Instil Bio, Inc.

    (Name of Issuer)

     

    Common Stock, $0.000001 par value

    (Title of Class of Securities)

     

    45783C101

    (CUSIP Number)

     

    March 23, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

      CUSIP No. 45783C101 Page 2 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 3 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 4 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 5 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                       

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 6 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 7 of 17

     

         
    1.  

    Name of reporting persons

     

    VHCP Management II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 8 of 17

     

         
    1.  

    Name of reporting persons

     

    VHCP Management III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 9 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 10 of 17

     

               
    1.  

    Name of Reporting Persons

     

    Shah, Nimish

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 11 of 17

     

               
    1.  

    Name of Reporting Persons

     

    Koh, Bong

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    6,865,0762

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    6,865,0762

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,865,0762

    10.   Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    2  Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 128,212,253 shares of the Issuer’s Common Stock outstanding after the completion of its initial public offering, as reported in the Issuer’s final prospectus filed with the Securities and Exchange Commission on March 22, 2021.

     

     

     

     

      CUSIP No. 45783C101 Page 12 of 17

     

    Introductory Note: This Schedule 13G is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Instil Bio, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Instil Bio, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    3963 Maple Avenue, Suite 350

    Dallas, Texas 75219

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

     

     

     

      CUSIP No. 45783C101 Page 13 of 17

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.000001 per share

     

      (e) CUSIP Number

     

    45783C101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of April 15, 2021:

     

    Venrock Healthcare Capital Partners II, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings II, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners III, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings III, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners EG, L.P.   6,865,076 (1)
    VHCP Management II, LLC   6,865,076 (1)
    VHCP Management III, LLC   6,865,076 (1)
    VHCP Management EG, LLC   6,865,076 (1)
    Nimish Shah   6,865,076 (1)
    Bong Koh   6,865,076 (1)

     

      (b) Percent of Class as of April 15, 2021:

     

    Venrock Healthcare Capital Partners II, L.P.   5.4 %
    VHCP Co-Investment Holdings II, LLC   5.4 %
    Venrock Healthcare Capital Partners III, L.P.   5.4 %
    VHCP Co-Investment Holdings III, LLC   5.4 %
    Venrock Healthcare Capital Partners EG, L.P.   5.4 %
    VHCP Management II, LLC   5.4 %
    VHCP Management III, LLC   5.4 %
    VHCP Management EG, LLC   5.4 %
    Nimish Shah   5.4 %
    Bong Koh   5.4 %

     

      (c) Number of shares as to which the person has, as of April 15, 2021:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   0  
    VHCP Co-Investment Holdings II, LLC   0  
    Venrock Healthcare Capital Partners III, L.P.   0  
    VHCP Co-Investment Holdings III, LLC   0  
    Venrock Healthcare Capital Partners EG, L.P.   0  
    VHCP Management II, LLC   0  
    VHCP Management III, LLC   0  
    VHCP Management EG, LLC   0  
    Nimish Shah   0  
    Bong Koh   0  

     

     

     

     

      CUSIP No. 45783C101 Page 14 of 17

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings II, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners III, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings III, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners EG, L.P.   6,865,076 (1)
    VHCP Management II, LLC   6,865,076 (1)
    VHCP Management III, LLC   6,865,076 (1)
    VHCP Management EG, LLC   6,865,076 (1)
    Nimish Shah   6,865,076 (1)
    Bong Koh   6,865,076 (1)

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   0  
    VHCP Co-Investment Holdings II, LLC   0  
    Venrock Healthcare Capital Partners III, L.P.   0  
    VHCP Co-Investment Holdings III, LLC   0  
    Venrock Healthcare Capital Partners EG, L.P.   0  
    VHCP Management II, LLC   0  
    VHCP Management III, LLC   0  
    VHCP Management EG, LLC   0  
    Nimish Shah   0  
    Bong Koh   0  

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings II, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners III, L.P.   6,865,076 (1)
    VHCP Co-Investment Holdings III, LLC   6,865,076 (1)
    Venrock Healthcare Capital Partners EG, L.P.   6,865,076 (1)
    VHCP Management II, LLC   6,865,076 (1)
    VHCP Management III, LLC   6,865,076 (1)
    VHCP Management EG, LLC   6,865,076 (1)
    Nimish Shah   6,865,076 (1)
    Bong Koh   6,865,076 (1)

     

    (1) Consists of (i) 48,390 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 19,620 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 5,635,937 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 563,533 shares held by VHCP Co-Investment Holdings III, LLC and (v) 597,596 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

     

     

     

     

      CUSIP No. 45783C101 Page 15 of 17

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

      CUSIP No. 45783C101 Page 16 of 17

     


    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 15, 2021

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ David L. Stepp
    Its: General Partner   Name:   David L. Stepp
        Its:   Authorized Signatory
    /s/ David L. Stepp    
    Name:   David L. Stepp    
    Its:   Authorized Signatory    

     

    Bong Koh    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    
         
    Nimish Shah    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

     

     

     

      CUSIP No. 45783C101 Page 17 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement

     

    B: Power of Attorney for Nimish Shah

     

    C: Power of Attorney for Bong Koh

     

     

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Instil Bio, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 15th day of April, 2021.

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name:   David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ David L. Stepp
    Its: General Partner   Name:   David L. Stepp
        Its:   Authorized Signatory

    /s/ David L. Stepp  
    Name: David L. Stepp  
    Its: Authorized Signatory  

     

    Bong Koh    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

    Nimish Shah    
         
    /s/ David L. Stepp    
    David L. Stepp, Attorney-in-fact    

     

     

     

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 15th day of April, 2021.

     

    /s/ Nimish Shah  

     

     

     

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

      (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

      (ii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 15th day of April, 2021.

     

    /s/ Bong Koh  

     

     

     

    Get the next $TIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2026Buy → Neutral
    H.C. Wainwright
    1/6/2026$7.00Outperform → Neutral
    Robert W. Baird
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    More analyst ratings

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and CBO Laumas Sandeep sold $701,667 worth of shares (30,000 units at $23.39) and exercised 30,000 shares at a strike of $12.07 (SEC Form 4)

    4 - Instil Bio, Inc. (0001789769) (Issuer)

    9/12/25 5:00:55 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Binder Gwendolyn

    4 - Instil Bio, Inc. (0001789769) (Issuer)

    5/29/25 7:13:10 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Gibson Neil W

    4 - Instil Bio, Inc. (0001789769) (Issuer)

    5/29/25 7:12:03 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

    DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX: 1541.HK) ("ImmuneOnco") have entered into an agreement terminating their license and collaboration agreement for AXN-2510 and AXN-27M ("Termination Agreement"). Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to a limited license to Axion to wind

    1/6/26 7:00:00 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025 financial results and provided a corporate update. Recent Highlights: In September, ImmuneOnco, Instil's collaborator, presented updated data from additional patients with relapsed/refractory squamous non-small cell lung cancer treated with ‘2510 as monotherapy in a poster presentation at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.In October, Axion Bio, Instil's subsidiary, dosed the first patient in its Pha

    11/13/25 7:00:00 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

    ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) ("ImmuneOnco") presented preliminary efficacy and safety data of ‘2510 (IMM2510/AXN-2510) as monotherapy in a Phase 1 study of patients in China with previously treated squamous non-small cell lung

    9/10/25 7:00:00 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TIL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Instil Bio Inc.

    SCHEDULE 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    2/9/26 2:29:48 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Instil Bio, Inc. (0001789769) (Filer)

    1/6/26 5:00:13 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Instil Bio Inc.

    10-Q - Instil Bio, Inc. (0001789769) (Filer)

    11/13/25 7:08:27 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Instil Bio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Instil Bio from Buy to Neutral

    1/7/26 9:03:18 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Instil Bio from Outperform to Neutral and set a new price target of $7.00

    1/6/26 12:20:40 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio upgraded by Jefferies with a new price target

    Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

    1/7/25 8:29:55 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    View All

    Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerIn July, announced the Investigational Ne

    8/13/25 6:00:00 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

    DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of Instil, stated, "We are thrilled to welcome Dr. Freedman as Chief Medical Officer. Jamie's extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in adva

    6/2/25 7:00:00 AM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

    11/14/22 4:07:40 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    11/14/24 6:59:16 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    11/14/24 5:48:56 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

    10/25/24 9:42:03 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care